Back

Efficacy and safety of dapagliflozin in black, compared to white, patients with heart failure with reduced ejection fraction: Results from DAPA-HF

29 June 2021 (08:00 - 23:59)
Organised by:
Congress Presentation Part of: ePoster session Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2021

About the speaker

Photo
Doctor Kieran Docherty

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

738 More presentations in this session

Presentation thumbnail
Atrial lead insertion during cardiac implantable electronic devices implantation in patients with atrial arrhythmia on hospital admission, when does the struggle for sinus rhythm make sense?
Assistant Professor N. Radovanovic (Belgrade, RS)
Abstract Slides
Presentation thumbnail
Features of the remodeling of atria and pulmonary veins in CHF patients with paroxysmal AF and permanent AF
Assistant Professor V. Kirillova (Ekaterinburg, RU)
Abstract Slides
Presentation thumbnail
Rhythm control versus rate control in patients with atrial fibrillation and heart failure across the left ventricular ejection fraction spectrum
Doctor D. Moysidis (Zurich, CH)
Abstract Slides
Presentation thumbnail
Impact of cardiac contractility modulation on ventricular rhythm and conduction disorders in patients with heart failure with reduced ejection fraction and various forms of atrial fibrillation
Doctor A. Safiullina (Moscow, RU)
Abstract Slides
Presentation thumbnail
Was a difference between late and early new-onset of atrial fibrillation in non st-elevation myocardial infarction?
Doctor H. Santos (Lisboa, PT)
Abstract Slides

Access the full session

Session thumbnail
ePoster session

The Event

Event poster

Heart Failure 2021

29 June 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure
27 August 2021
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023
28 August 2023
thumbnail
Congress Presentation
Benefits of empagliflozin in Hispanics and non-Hispanics with heart failure: a sub-analysis of the EMPEROR-trials
20 May 2023
thumbnail
Congress Presentation
Effectiveness of dapagliflozin in patients with obstructive sleep apnea and heart failure with reduced ejection fraction
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources